secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-045628
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa receives FDA Rare Pediatric and Orphan Drug designations for (Z)-endoxifen in DMD; pauses MBC
--------------------------------------------------------------------------------

- FDA Rare Pediatric Disease and Orphan Drug designations granted for (Z)-endoxifen in Duchenne Muscular Dystrophy (Dec 2025/Jan 2026).
- Paused investment in metastatic breast cancer (MBC) to prioritize other oncology and rare disease programs.
- Cash and equivalents >$40M as of early 2026, supporting >1 year of working capital.
- Reverse stock split effective Feb 2, 2026 to regain Nasdaq listing compliance.
- I-SPY 2 combination therapy enrollment near complete; preliminary data expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526045628/0001193125-26-045628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526045628/atos-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-045628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer